Key result
Aspirin use for VTE prophylaxis in orthopaedic oncology was evaluated in a retrospective study of 130 patients, but only 73% received the intended treatment, preventing definitive conclusions.
Why the study?
Does aspirin prevent venous thromboembolism in orthopaedic oncology patients?
Population
130 orthopaedic oncology patients with diagnoses including metastatic carcinoma, myeloma, lymphoma, and…
Design
Editorial
Authors
Loading...
While aspirin is an attractive option for VTE prophylaxis in orthopaedic oncology, current evidence from small retrospective studies is insufficient to definitively support its universal use.
Does aspirin prevent venous thromboembolism in orthopaedic oncology patients?
While aspirin is an attractive option for VTE prophylaxis in orthopaedic oncology, current evidence from small retrospective studies is insufficient to definitively support its universal use.
Timothy A. Damron (2017) conducted an editorial in Orthopaedic oncology requiring VTE prophylaxis (n=130). Aspirin was evaluated on Venous thromboembolism (VTE). Aspirin use for VTE prophylaxis in orthopaedic oncology was evaluated in a retrospective study of 130 patients, but only 73% received the intended treatment, preventing definitive conclusions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: